Brief: Trinity Biotech Secures Key Regulatory Approval For Offshored And Outsourced Manufacturing Of Its Flagship Rapid Hiv Test
24/06/2025 13:10
June 24 (Reuters) - Trinity Biotech PLC TRIB.O: TRINITY BIOTECH SECURES KEY REGULATORY APPROVAL FOR OFFSHORED AND OUTSOURCED MANUFACTURING OF ITS FLAGSHIP RAPID HIV TEST, ACCELERATING STRATEGIC & FINANCIAL PERFORMANCE TRANSFORMATION TRINITY BIOTECH PLC - TO IMPLEMENT NEXT PHASE OF NEW TRINSCREEN HIV MANUFACTURING MODELIN Q3 2025 TRINITY BIOTECH PLC - RECEIVES WHO APPROVAL FOR OFFSHORED AND OUTSOURCED UPSTREAM MANUFACTURING OF TRINSCREEN HIV TEST Source text: ID:nGNX7S5Ql5 Further company coverage: TRIB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trinity Biotech
See all newsNASDAQ RESUMED AT 12:18 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:13 PM
Brief: Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
Brief: Trinity Biotech’S Trinovium Subsidiary Agrees To Collaborate With Echelon Data Centres To Develop Advanced Liquid Cooling Solutions For Ai Infrastructure
NASDAQ RESUMED AT 09:00 AM